Circa Completes Amalgamation with Sicame and the Sale of Circa’s Telecom Business
Calgary, Alberta–(Newsfile Corp. – April 14, 2023) – Circa Enterprises Inc. (TSVX: CTO) (“Circa“) and…
News
DISCO to Announce First Quarter of Fiscal Year 2023 Financial Results On May 10, 2023
Conference Call Scheduled for May 10, 2023 at 4:00 p.m. CT AUSTIN, Texas–(BUSINESS WIRE)–CS Disco,…
Seven Hills Realty Trust First Quarter 2023 Conference Call Scheduled for Tuesday, April 25th
NEWTON, Mass.–(BUSINESS WIRE)–Seven Hills Realty Trust (Nasdaq: SEVN) today announced that it will issue a…
PCTEL Schedules First Quarter 2023 Earnings Release
BLOOMINGDALE, Ill.–(BUSINESS WIRE)–PCTEL, Inc. (Nasdaq: PCTI), a leading global provider of wireless technology, announced today…
Williams to Report First-Quarter 2023 Financial Results on May 3; Earnings Conference Call and Webcast Scheduled for May 4
TULSA, Okla.–(BUSINESS WIRE)–Williams (NYSE: WMB) plans to announce its first-quarter 2023 financial results after the…
Senti Bio to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 14, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI)…
Senti Bio to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 14, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI)…
Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease…
Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease…
Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage…
Spero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage…
Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs
Event on May 22nd will feature Elias Reichel, M.D., Professor, Department of Ophthalmology, Tufts University…
Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs
Event on May 22nd will feature Elias Reichel, M.D., Professor, Department of Ophthalmology, Tufts University…
Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference
SEATTLE and VANCOUVER, British Columbia, April 14, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference
SEATTLE and VANCOUVER, British Columbia, April 14, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
CENTOGENE to Participate in Upcoming Conferences in April
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 14, 2023 (GLOBE NEWSWIRE) — Centogene N.V….
CENTOGENE to Participate in Upcoming Conferences in April
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, April 14, 2023 (GLOBE NEWSWIRE) — Centogene N.V….
Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis
Favorable safety and tolerability profile related to OCU400 investigational product candidate Initial clinical data from…
Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis
Favorable safety and tolerability profile related to OCU400 investigational product candidate Initial clinical data from…
TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the…